Literature DB >> 24127636

Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes.

Khaled Ezzedine1, Aurélie Le Thuaut, Thomas Jouary, Fabienne Ballanger, Alain Taieb, Sylvie Bastuji-Garin.   

Abstract

Non-segmental vitiligo (NSV) is an enigmatic disease with various clinical courses. To empirically identify underlying subtypes of NSV, we performed latent class analysis (LCA) of 717 consecutive patients with NSV seen between 2006 and 2012 and were analyzed. Median age was 32 yrs (14-45), median age at NSV onset was 18 yrs (8-32), and median NSV duration 5 yrs (0.75-78.5). A two-class model showed the best fit. Of the 717 patients, 280 (39%) belonged to LC1 and 437 (61%) to LC2. LC1 patients had high probabilities for early disease onset (<12 yrs), halo nevi, family history of premature hair greying, Koebner phenomenon, previous episodes of repigmentation, and family history of vitiligo. By contrast, LC2 patients were characterized by a late disease onset (after or at the age of 12 yrs, median age of 30 yrs) and acrofacial localization without any lesions on trunk or limbs. These two LCA classes (LC1, 'prepubertal onset'; LC2, 'post-pubertal onset') may help refining results from genome-wide association studies (GWAS) and allow a more accurate genotype-phenotype correlation and help defining more directed treatment protocols.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  endophenotype; latent class analysis; post-pubertal; prepubertal; vitiligo

Mesh:

Year:  2013        PMID: 24127636     DOI: 10.1111/pcmr.12186

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  4 in total

1.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Authors:  Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-05-19       Impact factor: 30.700

Review 2.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Reclassification of breast cancer: Towards improved diagnosis and outcome.

Authors:  Alexander P Landry; Zsolt Zador; Rashida Haq; Michael D Cusimano
Journal:  PLoS One       Date:  2019-05-22       Impact factor: 3.240

4.  A Nationwide, Multicentric Case-Control Study on Vitiligo (MEDEC-V) to Elicit the Magnitude and Correlates.

Authors:  Nilendu Sarma; Sayantani Chakraborty; Shital Poojary; B M Shashi Kumar; Lalit Kumar Gupta; Leelavathy Budamakuntla; Leishiwon Kumrah; Suchibrata Das; Ajay Govindrao Ovhal; Nirmal Kumar Mandal; Shuvankar Mukherjee; T V Anoop; Binod Kumar Thakur; L Eswari; Joan Felicita Samson; Krina Bharat Patel; Rajesh Rajagopalan; Sanjeev Gupta; Tejinder Kaur
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.